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Upon infection, Trypanosoma cruzi triggers a strong immune response that has both protective and pathological 
consequences. In this work, several important questions regarding protective immunity are reviewed. Emphasis is 
placed on recent studies of the important protective role of CD8+ T cells and on previous studies of immunisation of 
domestic T. cruzi reservoirs that sought to address practical vaccination problems. Research on the maturation of 
memory cells and studies indicating that the prevalence of T. cruzi-specific T-cell responses and a high frequency of 
committed CD8+ T cells are associated with better clinical outcomes are also reviewed. Additionally, animal models 
in which protection was achieved without immunopathological consequences are discussed. 
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Clinical studies indicate that Trypanosoma cruzi in-
fection results in a state of host resistance that controls 
parasite load after one to three months. Parasitemia lev-
els are high during the first few weeks of infection but 
decrease thereafter to almost undetectable levels, as in-
dicated by parasite detection using fresh blood mounts, 
hemocultures, xenodiagnosis or polymerase chain reac-
tion (PCR). Evidence that an otherwise progressive and 
lethal infection is usually suppressed by the immune 
system is provided by cases of reactivation or appear-
ance of atypical clinical presentations of acute T. cruzi 
infection in patients with acquired immunodeficiencies 
(Simao Ferreira 1999) or human immunodeficiency vi-
rus infections (Karp & Arwaerter 2007).
Experimental mouse models, in which primary and 
secondary inoculations with T. cruzi may be planned at 
desired sequences and intervals, have been used to demon- 
strate that control of parasite load and survival during 
the chronic phase are the effects of a general protective 
mechanism elicited by primary infection. When chroni-
cally infected mice are again challenged with virulent 
T. cruzi, they do not exhibit a pathological response, 
whereas naive control mice experience high parasite 
load and high mortality (Basombrío 1981). For many 
years, inoculations with an attenuated T. cruzi culture 
(TCC) strain, containing mostly epimastigote forms, 
provided our laboratory with a method of reliably in-
ducing protective immunity. This technique resulted in 
stronger immunity for a longer duration than either se-
lected recombinant T. cruzi antigens plus adjuvants or 
killed parasites. Although this method is not approved 
for human vaccination trials, it has allowed us to study 
practical questions pertaining to vaccination against T. 
cruzi in laboratory animals and domestic reservoirs.
Here, we review several important questions regard-
ing protective immunity against T. cruzi. Although there 
is a vast literature on the subject, we place emphasis on 
experiences from our laboratory. Many of these research 
questions are longstanding but have been reformulated 
as technical progress provides new perspectives.
Have animal models of Chagas disease contributed 
evidence for or against the theory of autoimmune 
pathogenesis?
It is tempting to hypothesise that the immune re-
sponse itself causes disease. From this perspective, one 
would expect to detect pathology when the immune sys-
tem is actively suppressing T. cruzi load. A first series of 
experiments in our laboratory used the virulent Tulahuen 
strain of T. cruzi, later identified as T. cruzi IIe (TCIIe), to 
induce primary and secondary infections in mice (Table). 
Blood parasite load and mortality were clearly reduced 
after the second challenge, but the mice nevertheless 
developed severe heart and muscle lesions (Basombrío 
1981). Studies using the T. cruzi I (TCI) lineage provided 
findings consistent with these results, showing that some 
TCI strains induced serious tissue lesions despite mini-
mal or undetectable parasitemia (Cardozo 2003). How-
ever, in several experiments in which a highly attenuated 
primary infection by the TCC strain (TCI lineage) (Di-
osque et al., unpublished observations) preceded a viru-
lent TCIIe challenge, many desirable vaccination effects 
were demonstrated without immunopathology (Basom-
brío et al. 1982). Taken together, these studies indicate 
that the relationship between parasite load, inflammation 
and pathology in T. cruzi infection is highly dependent 
on the lineage of the infecting parasite and that protec-
tive immunisation does not necessarily trigger an immu-
nopathological response. Therefore, immunisation with 
TCC parasites confers protection against re-challenge 
and does not lead to immunopathology, which would be 
expected in an autoimmunity context.
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What is the role of CD8+ T cells in Chagas disease? 
T. cruzi is an intracellular pathogen that replicates 
in the cytoplasm of a wide variety of mammalian host 
cells, including macrophages and cardiac myocytes. 
Robust CD4+ and CD8+ T-cell responses are needed to 
protect against this protozoan, since mice lacking either 
of these T-cell subsets succumb to infection (Tarleton et 
al. 1992, 1996, Padilla et al. 2007). In particular, CD8+ 
T cells are a critical component of protective immunity 
in both mouse models and human patients (Alvarez et 
al. 2008). The significant role of CD8+ T cells during T. 
cruzi infection is demonstrated by their predominance in 
non-lymphoid tissues not only in experimental models, 
but also in the myocardium of T. cruzi-infected cardiac 
patients (Vogt et al. 2008). CD4+ and CD8+ T cells also 
secrete interferon-γ (IFN-γ), which is crucial for activat-
ing macrophages that exert trypanocidal activity via ni-
tric oxide (Muñoz-Fernandez et al. 1992).
Although CD8+ T cells mount a substantial immune 
response against T. cruzi infection, the parasite may 
survive and establish a lifelong chronic infection in the 
host (Martin & Tarleton 2006, Tzelepis et al. 2006). This 
parasitic persistence contributes to the development of 
symptoms many years or decades after initial infection 
in approximately one-third of chronically infected indi-
viduals (Tarleton 2001, 2003).
What are the contributions of experimental mouse 
models to the analysis of T-cell responses to persis-
tent or resolved T. cruzi infections?
When T. cruzi infection occurs, the innate and 
acquired immune responses are characterised by the 
recruitment of dendritic cells, macrophages, natural killer 
(NK) cells, and B and T lymphocytes, as well as their 
secretion of soluble factors (cytokines and chemokines). 
Once parasite load is controlled in chronically infected 
mice, the majority of T. cruzi-specific CD8+ T cells dis-
play a T effector or T effector memory (TEM) phenotype 
(CD62Llo, CD122lo, CD127lo). This phenotype correlates 
with a late-differentiation pattern and its maintenance 
has been thought to be antigen-dependent (Martin & 
Tarleton 2005). However, after pathogen clearance by 
drug treatment, long-term exposure to T. cruzi does not 
exhaust pathogen-specific CD8+ T cells, which maintain 
their potential to address re-infection (Bustamante et al. 
2008). In this case, the development of a stable, antigen-
independent TCM (T central memory) cell population 
(CD62Lhi, CD122hi, CD127hi, CCR7hi, and increased Bcl-
2 expression) has been noted. This population provides 
better protective immunity upon re-challenge than T ef-
fector or TEM cells in chronically infected mice. The pos-
sibility that phenotypic reversion occurs after parasitic 
load is decreased has important implications in human 
disease, as it may represent a new means of assessing 
treatment efficacy.
The influence of parasite persistence on the immune 
response to T. cruzi has also been studied in our labora-
tory. We hypothesised that if a memory mechanism ope- 
rates in the absence of infection, long-term resistance 
to virulent reinoculation should persist regardless of 
whether the primary infection was cured. In support of 
this hypothesis, treatment of TCC-inoculated mice with 
benznidazole did not terminate resistance to virulent 
inocula administered as late as 330 days after primary 
infection (Basombrío et al. 2002b). However, TCC in-
oculation of drug-treated mice did diminish their long-
term (1 year) ability to resist secondary challenge. These 
observations suggest that both parasite persistence and 
immunological memory contribute to long-term resis-
tance to re-infection.
Is there a relationship between disease progression 
and the pattern of T-cell differentiation in T. cruzi-
infected humans?
During persistent human viral infection, antigen-
primed CD8+ T cells may be classified as having early, 
intermediate and late-differentiated phenotypes based 
on their sequential down-regulation of CCR7, CD28, 
and CD27 and up-regulation of cytotoxic factors (Ap-
pay et al. 2002, Appay & Rowland-Jones 2004). Protec-
tive immunity is best conferred by early-differentiated 
T cells, which possess potent proliferative capacity (Ap-
pay & Rowland-Jones 2004). Meanwhile, highly dif-
ferentiated T cells present signs of senescence during 
chronic infection, presumably due to exhaustion after 
persistent activation and restimulation (Barber et al. 
2006, Hinrichs et al. 2006).
In chronically T. cruzi-infected patients presenting 
severe disease, the phenotypic profile of the antigen-
experienced memory CD8+ T-cell population is enriched 
in fully differentiated memory CD45RAlo, CD27lo, 
CD28lo CD8+ T cells (Laucella et al. 2004). Similarly, a 
low frequency of T. cruzi-specific CD8+ T cells has been 
observed in these patients, perhaps due to less efficient 
generation of memory CD8+ T cells or more marked de-
cline in memory T-cell function over time. This apparent 
impairment of CD8+ T-cell responses is associated with 
an increased frequency of fully differentiated memory 
CD8+ T cells and a high apoptosis rate, possibly reflect-
ing CD8+ T-cell exhaustion (Alvarez et al. 2008). Con-
versely, more frequent T. cruzi-specific T-cell responses 
TABLE
Summary of studies on parasite load and histopathology after 







- Tul (IIe) +++ +++
Tul (IIe) Tul (IIe) ± +++
- TCC (I) - -
TCC (I) Tul (IIe) ± ±
- Wild isolates ± ++
TCC (I) Wild isolates ± ±
- PalDa1(I) ± +++
PalDa1(I): a T. cruzi isolate; TCC (I): T. cruzi culture I; Tul 
(IIe): Tulahuen IIe; ++: moderate;  +++: severe; ±: slight; -: 
not detectable.
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are associated with better clinical outcomes, suggesting 
that protection from infection is related to an increased 
prevalence of highly competent, early-differentiated 
CD8+ T cells, which has been observed in patients with 
mild or no disease symptoms (Albareda et al. 2006).
Is protective immunity capable of completely pre-
venting re-infection?
Vaccine testing in mice is primarily composed of 
measurements of acute-stage parasitemia and mortality. 
Some studies have adopted more sensitive determinations 
of parasitemia, including hemoculture (Machado et al. 
2006), xenodiagnosis (Basombrío et al. 1986, Basso et al. 
2007), histopathological studies (Basombrío & Besuschio 
1982, Basombrío et al. 1986, Machado et al. 2006, Hoft et 
al. 2007) and electrocardiographic measurements (Cuneo 
et al. 1989). However, perhaps the most stringent meth-
od of demonstrating the absence of infection or “sterile 
immunity” after inoculation is serological testing. To 
explore this possibility, we applied the complement-me-
diated lysis (CML) test developed by Krettli and Brener 
(1982) to a mouse model of T. cruzi infection that includ-
ed wild T. cruzi isolates as well as TCC and Tulahuen 
strains. While many animals appeared protected from 
re-infection based on several parasitemia detection tests, 
sub-patent infections were demonstrated by the presence 
of lytic antibodies. Nevertheless, a significant proportion 
of mice (8/18 for wild T. cruzi infection, 25/28 for Tula-
huen infection) lacked lytic antibodies, suggesting a com-
plete absence of re-infection in TCC strain-immunised 
mice (Gomez et al. 1996). The CML test demonstrated 
infection by the Tulahuen and wild isolates but not by 
the TCC strain, which, besides being attenuated, did not 
elicit lytic antibodies. However, recent experiments have 
demonstrated TCC parasite persistence by hemoculture 
and real-time PCR after immunosuppression of mice in-
fected with TCC trypomastigotes from tissue cultures 
(Padilla et al., unpublished observations). These results 
suggest that protective immunisation against T. cruzi can 
prevent re-infection after secondary challenge, although 
this strong immunity may be induced by a subpatent, im-
munizing infection. Field trials in dogs included negative 
indirect hemagglutination (IHA) tests that indicated the 
absence of infection in immunised animals (Basombrío 
et al. 1993). Although the CML and IHA tests are based 
on distinct reactions, the latter has also been used to infer 
therapeutic success in clinical settings.
Can the prevention of infection be gauged by pa-
rameters indicative of disease?
In “premunition” experiments in mice challenged 
with the Tulahuen strain TCIIe, re-infection lethality 
and blood parasite load were strongly suppressed. How-
ever, these mice suffered from severe muscle, intestine 
and heart histopathological lesions (Basombrío 1981). 
Using the same experimental design but replacing the 
Tulahuen strain with the attenuated TCC strain during 
primary infection, lethality and parasite load were again 
suppressed during secondary infection. Additionally, 
many measurable parameters of histopathological dam-
age, including inflammatory mononuclear infiltration, 
necrosis and fibrosis, indicated protective immunity 
without immunopathological side effects (Basombrío et 
al. 1982, Basombrío & Besuschio 1982).
In another experiment, the frequency of certain elec-
trocardiographical alterations, such as persisting auricu-
loventricular blocks, supraventricular tachycardia and 
sinus bradycardia was measured in T. cruzi-infected 
mice previously or never primed with TCC strain inoc-
ula (Fig. 1). The TCC-primed group displayed a signifi-
cant reduction in electrocardiographic alterations (Cu-
neo et al. 1989). Pathology of heart and skeletal muscle, 
tissue parasite load and inflammation, mortality and 
parasitemia were also reduced in T. cruzi-infected mice 
previously immunised with DNA vaccines containing 
the trans-sialidase family genes ASP-1, ASP-2, or TSA-1 
(Garg & Tarleton 2002, Vasconcelos et al. 2004).
Do the time intervals between immunisation and 
infection in experimental models properly mimic 
those of natural T. cruzi infection in the field?
 
Unfortunately, although the duration of protective im-
munity development is an important parameter, it is test-
ed and reported very infrequently for T. cruzi vaccines. 
The fact that protection by non-replicating T. cruzi anti-
gens is relatively short-lived (1-3 months) unless booster 
injections are provided probably precluded the investiga-
tion of many candidate immunogens. In this regard, the 
vaccination experiments of Machado et al. (2006), which 
used recombinant adenoviruses expressing two T. cruzi 
antigens in a replicating organism, are very promising, 
particularly since protection against re-infection was de-
monstrable 3 1/2 months after immunisation. Moreover, 
many of the immunised mice developed sterile immunity, 
as suggested by negative hemocultures, and all protected 
mice survived a 100% lethal challenge.
Tzelepis et al. (2006) studied the kinetics of the CD8+ 
T-cell cytotoxic response and IFN-γ secretion after in-
Fig. 1: prevention of electrocardiographic (ECG) alterations in mice 
by pre-inoculation of TCC epimastigotes. First degree AV blocks, 
sinus bradycardia and supraventricular tachycardia; INFECT: mice 
inoculated with virulent Trypanosoma cruzi; INM: only received 
T.cruzi culture (TCC) inoculations; INM-INF: same as INFECT, but 
pre-inoculated with attenuated TCC T. cruzi; NORM: non inoculated 
mice (data from Cuneo et al. 1989).
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fection of naive mice or mice vaccinated with trans-sial-
idase or ASP-2 antigens. Following peak parasitemia, 
these responses reached a maximum around days 15-
30 of infection, subsequently declining slowly but still 
detectable by day 240. In particular, cytotoxic activity 
against ASP-2 peptide-coated cells was remarkably high 
eight months after initial infection. While the cytotoxic 
response peaked after the highest parasitemia level in 
naive mice, vaccinated mice responded much more rap-
idly, leading to more successful protection. Inoculation 
with the TCC strain induces lifetime resistance to rein-
oculation with virulent wild T. cruzi isolate, as tested 
with inocula administered 312, 366 or 436 days after pri-
mary TCC infection (Basombrío & Arredes 1987). Thus, 
the duration of the development of protective immunity 
prior to re-infection seems essential to vaccination in the 
field. The importance of this time interval between pri-
mary and secondary infection in the field may explain 
why killed T. cruzi vaccines that were highly protective 
in laboratory tests were only weakly protective in field 
tests on guinea pigs (Basombrío 1990).
Is resistance to the Tulahuen strain induced by at-
tenuated TCC inoculation also applicable to a variety 
of wild T. cruzi isolates?
Vaccine development is often hampered by antigenic 
modulation and pathogenic diversity. These survival 
mechanisms, allowing pathogens to evade the protective 
effects of vaccines, are well characterised for influenza 
and papillomavirus and may also be utilised by Plasmo-
dium sp., Giardia sp. and African trypanosomes. How-
ever, there is no evidence that vaccines protective against 
particular T. cruzi laboratory strains will fail when tested 
against wild parasites. In fact, it has been found that the 
attenuated TCC strain belonging to lineage I (TCI) may 
confer protection against a secondary challenge with 
the lineage II Tulahuen strain (Basombrio & Besuschio 
1982). Moreover, we challenged TCC-immunised mice 
with a battery of 17 wild T. cruzi isolates derived from 
insect vectors within a 50,000 km2 area of Northern Ar-
gentina. The TCC immunisation conferred a significant 
degree of protection against wild parasites in all cases, 
as tested by blood mount, xenodiagnosis and histopatho-
logical studies (Basombrío et al. 1986).
Is the acquired immunity demonstrated in immu-
nised laboratory mice also operative against natural 
reservoirs of T. cruzi, such as dogs and guinea pigs 
infected with wild T. cruzi by insect vectors?
Most testing of experimental T. cruzi vaccines has 
been performed under laboratory conditions, which 
may differ significantly from a field setting. Blood-
borne trypomastigotes of a laboratory T. cruzi strain are 
typically injected intraperitoneally or subcutaneously 
into mice after a short, uniform vaccination-challenge 
interval. In contrast, a field test of the same vaccine re-
quires vectorial inoculation of insect-borne, wild forms 
of the parasite at mucosal or intradermal sites in mam-
mals known as natural T. cruzi reservoirs. This protocol 
also includes relatively long and highly variable vacci-
nation-challenge intervals.
One approach to testing immunity against “natural” 
infection modalities is oral delivery of vector-borne 
trypomastigotes in mice, allowing exploration of the 
particular effectors of mucosal immunity. For example, 
vaccines composed of recombinant trans-sialidase and 
the adjuvant oligodeoxynucleotide CPG-ODN were 
found to be effective, even when administered intra-
nasally, against secondary oral challenge with T. cruzi 
(Hoft et al. 2007).
Guinea pigs, which are both domestic reservoirs of 
T. cruzi and a convenient experimental model, gave us 
the opportunity to perform vaccination studies in isolat-
ed field yards colonised by Triatoma infestans vectors. 
TCC parasite cultures used in a live-attenuated vaccine 
were shown to be unable to propagate outside culture or 
to feed the natural transmission cycle. After five repli-
cations of the experiment, the rate of natural infection, 
as tested by xenodiagnosis, had been reduced to 39% 
in animals preinoculated with 107 TCC culture forms, 
as compared with 63% in control guinea pigs (p < 0.02) 
(Fig. 2). After publication of these results (Basombrío et 
al. 1987), 10 additional experimental series involving a 
total of 149 control and 157 vaccinated guinea pigs dem-
onstrated a significant degree of protection in the latter 
group, with infection rates reaching 57.7% and 36.3%, 
respectively (p < 0.001).
Following pioneering work conducted in Brazil (Me-
nezes 1969), we attempted experimental vaccination in 
dogs. Like guinea pigs, dogs are important domestic res-
ervoirs of T. cruzi, displaying high rates of natural infec-
tion in some subtropical areas of the Santiago del Estero 
province of Argentina. In this region, a house-to-house 
survey allowed the selection of 219 uninfected animals, 
which were randomised either to be vaccinated with two 
inoculations of TCC live-attenuated cultures or to re-
main untreated (Basombrío et al. 1993). After one year 
of natural exposure to vectors, T. cruzi infection was 
examined by means of xenodiagnosis and serological 
hemmaglutination reactions in 148 dogs. It was found 
that the natural T. cruzi infection rate, determined using 
Fig. 2: positivity rate of xenodiagnosis in guinea pigs preinoculated 
with culture forms of the attenuated Trypanosoma cruzi culture strain 
(experimental) and non-immunized (controls) after uniform exposure 
to vectorial T. cruzi transmission in experimental corrals (data from 
Basombrío et al. 1987).
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the control group (20/75; 26.7%) had been reduced (9/73; 
12.3%) in the vaccinated animals (p < 0.015) (Fig. 3). 
This trial indicated that natural T. cruzi infection of dogs 
is an epidemiological condition that may be improved 
by vaccination, which may help to reduce the risk of 
spreading infection to humans.
Can measurements of parasite trafficking in the 
transmission cycle inform assessment of protective 
immunity?
Several successful vaccines exert a “herd effect” in 
addition to protecting the individual, whereby transmis-
sion of the target pathogen from vaccinated to non-vacci-
nated hosts is partially blocked. Theoretically, this effect 
may be measured for the complex host-vector transmis-
sion cycle of T. cruzi in two ways. Host-to-vector traf-
fic can be correlated to the host’s ability to transfer the 
parasite to uninfected insect vectors. This measurement 
may be obtained by using xenodiagnosis to quantify the 
proportion of insects infected after a standardised blood 
meal from a single host. Meanwhile, vector-to-host traf-
fic can be correlated to the ability of insect vectors to 
transmit the infection to new hosts. This measurement 
can be obtained by determining the number of bites nec-
essary for infection (NBNI), a calculation applicable to 
T. cruzi transmission in standardised guinea pig yards 
(Basombrío et al. 1996).
Host-to-vector traffic was measured during several 
experiments in which guinea pigs living in T. infestans-
colonised yards were vaccinated with live-attenuated T. 
cruzi. Totals of 2,040 and 1,960 insects were allowed to 
feed on control and vaccinated guinea pigs, respectively, 
and were then studied for infection in pools of 10. The 
positivity rate in xenodiagnosis was 38% for controls 
and only 18% for vaccinated animals (p < 0.001) (Ba-
sombrío et al. 1987).
A similar measurement was performed in vaccinated 
dogs. Here, the insects were not analysed in pools but 
individually and xenodiagnoses of uninfected dogs were 
excluded from the study. Again, the positivity rate was 
significantly reduced in the vaccinated group, from 52% 
in control animals to 29% (p < 0.001) (Basombrío et al. 
1993). Taken together, the results indicate that in both 
guinea pigs and dogs subjected to an environment of 
high vectorial T. cruzi transmission, the force of host-to-
vector infection was reduced by vaccination. The reduc-
tion of T. cruzi transmission from dogs to T. infestans 
after experimental vaccination has also been confirmed 
by Basso et al. (2007).
Vector-to-host T. cruzi traffic, as measured by NBNI 
determinations, was estimated in guinea pig yard ex-
periments. Parameters such as days of exposure, average 
number of insects per guinea pig, proportion of infected 
vectors, proportion of fed vectors, number of guinea pigs 
and proportion of hosts infected were controlled. Whereas 
an average of 4,973 bites was calculated to infect a control 
guinea pig, an average of 21,307 bites (a 4.28-fold increase) 
was necessary to produce the same effect in a vaccinated 
animal (Basombrío et al. 1997). These results suggest that 
the effects of protective immunisation on domestic mam-
malian reservoirs of T. cruzi may be measured not only in 
terms of parasite load, disease and mortality, but also in 
terms of vectorial parasite traffic (Fig. 4).
In conclusion, protective immunity against T. cruzi 
has been well demonstrated in both humans and experi-
mental animal models. However, many escape mecha-
nisms exist whereby parasites may overcome host pro-
tective immunity. While T. cruzi implements some of 
these mechanisms, it is unable to generate diverse anti-
genic lineages or to switch membrane antigens rapidly, 
which would preclude vaccination. Recent advances 
toward the development of genetically modified para-
sites capable of inducing a protective immune response 
without causing pathology present a promising new ap-
Fig. 4: estimated number of vector bites necessary to infect a guinea pig 
(NBNI), as measured in animals preinoculated with culture forms of 
the attenuated TCC Trypanosoma cruzi strain (black bars) and controls 
(white bars). Animals were exposed to controlled vectorial transmission 
in experimental corrals. Four separate experiments are represented. 
Each experiment was evaluated a two different times, generating eight 
comparable measurements, represented by a black and a white bar (data 
from Basombrío et al. 1997).
Fig. 3: diagrams representing Trypanosoma cruzi infection of dogs 
after natural exposure to vectorial transmission in Santiago del Es-
tero, Argentina. The experimental group was preinoculated with cul-
ture forms of the attenuated T. cruzi culture (TCC) strain. A: each 
dot represents one dog (black: preinoculated with TCC; white: non 
immunized controls);  and : infected;  and : not infected; B: 
percentage of infected dogs in each group, as detected by xenodiag-
nosis (data from Basombrío et al. 1993).
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proach to vaccination against T. cruzi (Basombrío et al. 
2002a, Barrio et al. 2007, Zago et al. 2008). Beyond re-
ducing immunopathology, such a vaccine would poten-
tially establish robust, long-lasting protection without 
parasite persistence.
Do we need a human T. cruzi vaccine at present? The 
success of well-established vector control and alterna-
tive prevention methods indicates that a human vaccine 
is not imperative but that vaccination of domestic reser-
voirs may be desirable in some cases of Chagas disease. 
However, epidemiological situations do change over 
decades, such as the development of insecticide resis-
tance by vectors or the appearance of new transmission 
modalities. In these situations, the need for additional 
prevention methods, including vaccination, may arise.
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